Genetic Variability of SNP rs7089580 in latin american populations and its impact on Warfarin dosage
DOI:
https://doi.org/10.56294/dm2024440Keywords:
SNP rs7089580, Warfarin Dosage, Genetic Variability, Latin American Populations, Personalized MedicineAbstract
Introduction: genetic variability in genes that encode drug metabolizing enzymes can influence the response to medications and the doses necessary for an adequate therapeutic effect. In the case of warfarin, a widely used anticoagulant, the enzyme CYP2C9 is responsible for metabolizing its active enantiomer, S-warfarin.
Method: the frequencies of the T allele of the SNP rs7089580 were analyzed in Latin American populations using data from the 1000 Genomes Project. Tools such as VCFtools were used to determine the frequency of the T allele and the Hardy-Weinberg equilibrium (HW) and linkage disequilibrium (LD) between the SNP rs7089580 and the promoter SNP rs12251841 of the CYP2C9 gene were evaluated.
Results: the frequencies of the T allele vary significantly between populations, with the Puerto Rican population presenting the highest frequency (17 %) and the Peruvian population the lowest (4 %). The results show that Latin American populations are in HW equilibrium, suggesting stability in genetic frequencies.
Conclusions: the variability in the frequency of the T allele of the SNP rs7089580 in Latin American populations reflects the complex genetic mix of the region. The balance of HW and the strong linkage disequilibrium between the SNPs suggest that rs7089580 may be a useful marker to predict CYP2C9 expression and response to warfarin
References
1.Tosca EM, De Carlo A, Ronchi D, Magni P. Model-Informed Reinforcement Learning for Enabling Precision Dosing Via Adaptive Dosing. Clin Pharmacol Ther. 2024;10.1002/cpt.3356. https://doi.org/10.1002/cpt.3356
2. Cross B, Turner RM, Zhang JE, Pirmohamed M. Being precise with anticoagulation to reduce adverse drug reactions: are we there yet?. Pharmacogenomics J. 2024;24(2):7. https://doi.org/10.1038/s41397-024-00329-y
3. Takahashi H, Echizen H. Pharmacogenetics of warfarin elimination and its clinical implications. Clin Pharmacokinet. 2001;40(8):587-603. https://doi.org/10.2165/00003088-200140080-00004
4. Perera MA, Cavallari LH, Limdi NA, et al. Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study. Lancet. 2013;382(9894):790-796. https://doi.org/10.1016/S0140-6736(13)60991-8
5. Rieder MJ, Reiner AP, Gage BF, Nickerson DA, Eby CS, McLeod HL, Rettie AE. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med. 2005;352(22):2285-2293. https://doi.org/10.1056/NEJMoa044503
6. Hernandez W, Aquino-Michaels K, Drozda K, Patel S, Jeong H, Takahashi H, Cavallari LH, Perera MA. Novel SNP in CYP2C9 is associated with changes in warfarin clearance and CYP2C9 expression levels in African Americans. Transl Res. 2015;165(6):651-657. https://doi.org/10.1016/j.trsl.2014.11.006
7. Hernandez W, Gamazon ER, Aquino-Michaels K, et al. Ethnicity-specific pharmacogenetics: the case of warfarin in African Americans. Pharmacogenomics J. 2013;13(3):201-207. https://doi.org/10.1038/tpj.2012.21
8. Sun B, Wen YF, Culhane-Pera KA, Lo M, Straka RJ. Pharmacogenomic variabilities in geo-ancestral subpopulations and their clinical implications: Results of collaborations with Hmong in the United States. Front Genet. 2023;13:1070236. https://doi.org/10.3389/fgene.2022.1070236
9. 1000 Genomes Project Consortium. A global reference for human genetic variation. Nature. 2015;526(7571):68-74. https://doi.org/10.1038/nature15393
10. Ruiz-Linares A, Adhikari K, Acuña-Alonzo V, Quinto-Sanchez M, Jaramillo C, Arias W, et al. Admixture in Latin America: Geographic Structure, Phenotypic Diversity and Self-Perception of Ancestry Based on 7,342 Individuals. PLoS Genet. 2014;10(9). https://doi.org/10.1371/journal.pgen.1004572
Published
Issue
Section
License
Copyright (c) 2024 Sergio V. Flores , Román M. Montaña, Angel Roco-Videla, Marcela Caviedes-Olmos, Sofía Pérez-Jiménez, Raúl Aguilera Eguía (Author)
This work is licensed under a Creative Commons Attribution 4.0 International License.
The article is distributed under the Creative Commons Attribution 4.0 License. Unless otherwise stated, associated published material is distributed under the same licence.
